Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)

Apatinib, a VEGFR2 receptor tyrosine kinase inhibitor, showed survival benefits in Asian patients with heavily pretreated advanced gastric cancer. However, the adverse event (AEs) profile of apatinib has limited its use. Dosing schedules are used to alleviate toxicities despite no supportive evidenc...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Am J Cancer Res
Egile Nagusiak: Wang, Xiang, Yu, Junyan, Yang, Mudan, Liu, Likun, Gao, Jinghua, Ren, Yuchuan, Zhang, Ruixing, Zhong, Diansheng, Du, Nan, Fu, Zhanzhao, Jia, Junmei, Li, Qingshan, Diao, Jianfeng, Zhang, Junping, Guo, Jun, Li, Xiaomei, Song, Xiang, Zhang, Yan, Yu, Zhonghe, Ma, Liwen, Fan, Zaiwen, Liu, Zheng, Li, Guozhong, Liang, Feng, Wang, Huaqing, Gao, Yunge, Yang, Ping, Bai, Chunmei, Zang, Aimin, Ren, Xiubao
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: e-Century Publishing Corporation 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7136926/
https://ncbi.nlm.nih.gov/pubmed/32266105
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak